Peptonic Medical (PMED) Q2 2026 earnings summary

Executive summary

• Sales of goods decreased by 52% to 2,360 KSEK in Q2 2026 compared to Q2 2025, with a gross margin of 60% versus 97% last year.

• Operating loss widened slightly to -3,711 KSEK in Q2 2026 from -3,489 KSEK in Q2 2025.

• Strategic focus sharpened post-restructuring, with reduced cost base and new product launches supporting growth ambitions.

• First commercial delivery to a US partner marks a milestone in international expansion.

Financial highlights

• Q2 2026 sales: 2,360 KSEK (down from 4,912 KSEK in Q2 2025); H1 2026 sales: 5,498 KSEK (down from 8,670 KSEK in H1 2025).

• Gross profit in Q2 2026: 1,415 KSEK (Q2 2025: 4,783 KSEK); gross margin 60% (Q2 2025: 97%).

• Operating expenses in Q2 2026: -6,577 KSEK, down 32% year-over-year.

• Net result for Q2 2026: -3,837 KSEK (Q2 2025: -3,535 KSEK).

• Cash at June 30, 2026: 758 KSEK (June 30, 2025: 5,667 KSEK).

Outlook and guidance

• Focus remains on product development, sales growth, and brand building.

• Updated CE marking for Vernivia expected in autumn, enabling relaunch.

• Strengthened financial position and lower cost base support continued commercial development.